Unknown

Dataset Information

0

CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms.


ABSTRACT: Suspicion of myeloproliferative neoplasms (MPNs) and especially essential thrombocythemia (ET) in primary care is often based solely on blood counts, with patients referred to a haematologist without a thorough evaluation. We retrospectively assessed the role of calreticulin gene (CALR) mutations in the diagnosis of MPN in this population. We studied CALR mutations in 524 JAK2 V617F-negative patients with suspected MPN. Uncommon CALR mutations were confirmed by Sanger sequencing and searched for in the COSMIC or HGMD database. Mutations were defined as frameshift or non-frameshift mutations. CALR mutations were detected in 23 patients (23/524?=?4.4%). Four mutations detected in our study were newly identified mutations. Non-frameshift mutations were detected in two patients. Most patients (380/524?=?72.5%) were diagnosed with secondary conditions leading to blood count abnormalities such as iron deficiency, inflammatory and infectious diseases, malignancy and hyposplenism. Nine patients (9/23?=?39%) were retrospectively diagnosed with ET based on CALR mutation confirmation. Two patients with non-frameshift CALR mutations were diagnosed with reactive thrombocytosis and MPN unclassifiable, respectively. Our study showed that CALR mutations are important, non-invasive diagnostic indicators of ET and can aid in its diagnosis. Moreover, the type of CALR mutation must be accurately defined, as non-frameshift mutations may not be associated with ET. Finally, CALR mutation detection should be reserved for patients with high suspicion of clonal haematological disease.

SUBMITTER: Belcic Mikic T 

PROVIDER: S-EPMC6934448 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms.

Belcic Mikic Tanja T   Pajic Tadej T   Sever Matjaz M  

Scientific reports 20191227 1


Suspicion of myeloproliferative neoplasms (MPNs) and especially essential thrombocythemia (ET) in primary care is often based solely on blood counts, with patients referred to a haematologist without a thorough evaluation. We retrospectively assessed the role of calreticulin gene (CALR) mutations in the diagnosis of MPN in this population. We studied CALR mutations in 524 JAK2 V617F-negative patients with suspected MPN. Uncommon CALR mutations were confirmed by Sanger sequencing and searched for  ...[more]

Similar Datasets

| S-EPMC9587876 | biostudies-literature
| S-EPMC3966280 | biostudies-literature
| S-EPMC10726695 | biostudies-literature
| S-EPMC3551963 | biostudies-literature
| S-EPMC3672250 | biostudies-literature
| S-EPMC8307561 | biostudies-literature
| S-EPMC4223390 | biostudies-literature
| S-EPMC6616334 | biostudies-literature
| S-EPMC3960525 | biostudies-literature
| S-EPMC5085254 | biostudies-literature